Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

BACKGROUND: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxyge...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jason D., Lye, David C.B., Hui, David S., Marks, Kristen M., Bruno, Raffaele, Montejano, Rocio, Spinner, Christoph D., Galli, Massimo, Ahn, Mi-Young, Nahass, Ronald G., Chen, Yao-Shen, SenGupta, Devi, Hyland, Robert H., Osinusi, Anu O., Cao, Huyen, Blair, Christiana, Wei, Xuelian, Gaggar, Anuj, Brainard, Diana M., Towner, William J., Muñoz, Jose, Mullane, Kathleen M., Marty, Francisco M., Tashima, Karen T., Diaz, George, Subramanian, Aruna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377062/
https://www.ncbi.nlm.nih.gov/pubmed/32459919
http://dx.doi.org/10.1056/NEJMoa2015301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377062/
https://www.ncbi.nlm.nih.gov/pubmed/32459919
http://dx.doi.org/10.1056/NEJMoa2015301

Ejemplares similares